BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou YW, Xie Y, Tang LS, Pu D, Zhu YJ, Liu JY, Ma XL. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduct Target Ther 2021;6:317. [PMID: 34446699 DOI: 10.1038/s41392-021-00733-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Brindani N, Munafò F, Menichetti A, Donati E, Nigro M, Ottonello G, Armirotti A, De Vivo M. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. Bioorg Med Chem 2023;80:117179. [PMID: 36716583 DOI: 10.1016/j.bmc.2023.117179] [Reference Citation Analysis]
2 Nasrollahi H, Talepoor AG, Saleh Z, Eshkevar Vakili M, Heydarinezhad P, Karami N, Noroozi M, Meri S, Kalantar K. Immune responses in mildly versus critically ill COVID-19 patients. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1077236] [Reference Citation Analysis]
3 Nolan MB, Piasecki TM, Smith SS, Baker TB, Fiore MC, Adsit RT, Bolt DM, Conner KL, Bernstein SL, Eng OD, Lazuk D, Gonzalez A, Hayes-Birchler T, Jorenby DE, D'Angelo H, Kirsch JA, Williams BS, Kent S, Kim H, Lubanski SA, Yu M, Suk Y, Cai Y, Kashyap N, Mathew J, McMahan G, Rolland B, Tindle HA, Warren GW, Abu-El-Rub N, An LC, Boyd AD, Brunzell DH, Carrillo VA, Chen LS, Davis JM, Deshmukh VG, Dilip D, Goldstein AO, Ha PK, Iturrate E, Jose T, Khanna N, King A, Klass E, Lui M, Mermelstein RJ, Poon C, Tong E, Wilson KM, Theobald WE, Slutske WS. Relations of Current and Past Cancer with Severe Outcomes among 104,590 Hospitalized COVID-19 Patients: The COVID EHR Cohort at the University of Wisconsin. Cancer Epidemiol Biomarkers Prev 2023;32:12-21. [PMID: 35965473 DOI: 10.1158/1055-9965.EPI-22-0500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chopra A, Shukri AH, Adhikary H, Lukinović V, Hoekstra M, Cowpland M, Biggar KK. A peptide array pipeline for the development of Spike-ACE2 interaction inhibitors. Peptides 2022;158:170898. [PMID: 36279985 DOI: 10.1016/j.peptides.2022.170898] [Reference Citation Analysis]
5 Gandhi Y, Mishra SK, Rawat H, Grewal J, Kumar R, Shakya SK, Jain VK, Babu G, Singh A, Singh R, Acharya R, Kumar V. Phytomedicines explored under in vitro and in silico studies against coronavirus: An opportunity to develop traditional medicines. S Afr J Bot 2022;151:451-83. [PMID: 35530267 DOI: 10.1016/j.sajb.2022.04.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen N, Zhang B, Deng L, Liang B, Ping J. Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2. Emerg Microbes Infect 2022;11:1371-89. [PMID: 35476817 DOI: 10.1080/22221751.2022.2071175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jing H, Wu X, Xiang M, Liu L, Novakovic VA, Shi J. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.992384] [Reference Citation Analysis]
8 Zerrouki A, Abrigach F, Taleb M, Kadiri SE. Towards potent Covid-19 spike protein inhibitors and catecholase activity agents: Synthesis, ADME-Tox analysis and molecular docking of new 1,2,4- triazole-based molecules.. [DOI: 10.21203/rs.3.rs-2238807/v1] [Reference Citation Analysis]
9 Shen Y, Eades W, Liu W, Yan B. The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro. Drug Metab Dispos 2022;50:1151-60. [PMID: 35790245 DOI: 10.1124/dmd.122.000918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Srivastava BBL, Ripanda AS, Mwanga HM. Ethnomedicinal, Phytochemistry and Antiviral Potential of Turmeric (Curcuma longa). Compounds 2022;2:200-221. [DOI: 10.3390/compounds2030017] [Reference Citation Analysis]
11 Zhao H, To KK, Lam H, Zhang C, Peng Z, Meng X, Wang X, Zhang AJ, Yan B, Cai J, Yeung ML, Chan JF, Yuen KY. A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters. Cell Discov 2022;8:62. [PMID: 35768416 DOI: 10.1038/s41421-022-00428-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Qin R, Kurz E, Chen S, Zeck B, Chiribogas L, Jackson D, Herchen A, Attia T, Carlock M, Rapkiewicz A, Bar-sagi D, Ritchie B, Ross TM, Mahal LK. α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade.. [DOI: 10.1101/2022.06.06.22275981] [Reference Citation Analysis]
13 Lan Y, He W, Wang G, Wang Z, Chen Y, Gao F, Song D. Potential Antiviral Strategy Exploiting Dependence of SARS-CoV-2 Replication on Lysosome-Based Pathway. IJMS 2022;23:6188. [DOI: 10.3390/ijms23116188] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Teixeira LMC, Coimbra JTS, Ramos MJ, Fernandes PA. Transmembrane Protease Serine 2 Proteolytic Cleavage of the SARS-CoV-2 Spike Protein: A Mechanistic Quantum Mechanics/Molecular Mechanics Study to Inspire the Design of New Drugs To Fight the COVID-19 Pandemic. J Chem Inf Model 2022;62:2510-21. [PMID: 35549216 DOI: 10.1021/acs.jcim.1c01561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bilal MY. Similarity Index-Probabilistic Confidence Estimation of SARS-CoV-2 Strain Relatedness in Localized Outbreaks. Epidemiologia (Basel) 2022;3:238-49. [PMID: 36417255 DOI: 10.3390/epidemiologia3020019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang W, Li Q, Sun J, Huat Tan S, Tang Y, Zhao M, Li Y, Cao X, Zhao J, Yang J. Potential Drug Discovery for COVID-19 Treatment Targeting Cathepsin L Using a Deep Learning-Based Strategy. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dumache R, Enache A, Macasoi I, Dehelean CA, Dumitrascu V, Mihailescu A, Popescu R, Vlad D, Vlad CS, Muresan C. SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. Pathogens 2022;11:516. [DOI: 10.3390/pathogens11050516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Sahoo T, Subba Reddy B. Concise synthesis of antiviral drug, Molnupiravir by direct coupling of fully protected D-Ribose with cytosine. Tetrahedron Letters 2022. [DOI: 10.1016/j.tetlet.2022.153783] [Reference Citation Analysis]
19 Choudhury C, Arul Murugan N, Deva Priyakumar U. Structure-based drug repurposing: traditional and advanced AI/ML-aided methods. Drug Discov Today 2022:S1359-6446(22)00112-X. [PMID: 35301148 DOI: 10.1016/j.drudis.2022.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Qiu C, Whittaker GR, Gellman SH, Daniel S, Abbott NL. Characterization of Hydrophobic Interactions of SARS-CoV-2 and MERS-CoV Spike Protein Fusion Peptides Using Single Molecule Force Measurements.. [DOI: 10.1101/2022.03.05.483104] [Reference Citation Analysis]
21 Chen C, Lin S, Shen C, Hsieh K, Cheng C. Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes. Diagnostics 2022;12:509. [DOI: 10.3390/diagnostics12020509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
22 Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
23 Bignardi E, Brogna C, Capasso C, Brogna B. A fatal case of COVID-19 breakthrough infection due to the delta variant. Clin Case Rep 2022;10:e05232. [PMID: 35035958 DOI: 10.1002/ccr3.5232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 El Hassab MA, Eldehna WM, Al-Rashood ST, Alharbi A, Eskandrani RO, Alkahtani HM, Elkaeed EB, Abou-Seri SM. Multi-stage structure-based virtual screening approach towards identification of potential SARS-CoV-2 NSP13 helicase inhibitors. J Enzyme Inhib Med Chem 2022;37:563-72. [PMID: 35012384 DOI: 10.1080/14756366.2021.2022659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
25 Islam KU, A-Elgadir TME, Afaq S, Ahmad T, Iqbal J. Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. Front Pharmacol 2021;12:778219. [PMID: 35002711 DOI: 10.3389/fphar.2021.778219] [Reference Citation Analysis]
26 Amoutzias GD, Nikolaidis M, Tryfonopoulou E, Chlichlia K, Markoulatos P, Oliver SG. The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2. Viruses 2022;14:78. [PMID: 35062282 DOI: 10.3390/v14010078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 24.0] [Reference Citation Analysis]
27 Huang H, Hu PF, Sun LL, Guo YB, Wang Q, Liu ZM, Yin JZ, Shi PM, Yuan ZL, Xie WF. Treatment of patients with Covid-19 with a high dose of ulinastatin. Exp Ther Med 2022;23:121. [PMID: 34970344 DOI: 10.3892/etm.2021.11044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.01.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
29 Papi M, Pozzi D, Palmieri V, Caracciolo G. Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting. Nano Today 2022. [DOI: 10.1016/j.nantod.2022.101403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Ambike S, Cheng CC, Feuerherd M, Velkov S, Baldassi D, Afridi SQ, Porras-Gonzalez D, Wei X, Hagen P, Kneidinger N, Stoleriu MG, Grass V, Burgstaller G, Pichlmair A, Merkel OM, Ko C, Michler T. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res 2021:gkab1248. [PMID: 34928377 DOI: 10.1093/nar/gkab1248] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Zannella C, Rinaldi L, Boccia G, Chianese A, Sasso FC, De Caro F, Franci G, Galdiero M. Regulation of m6A Methylation as a New Therapeutic Option against COVID-19. Pharmaceuticals (Basel) 2021;14:1135. [PMID: 34832917 DOI: 10.3390/ph14111135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
32 Tao X, Zhang L, Du L, Liao R, Cai H, Lu K, Zhao Z, Xie Y, Wang PH, Pan JA, Zhang Y, Li G, Dai J, Mao ZW, Xia W. Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate. Chem Sci 2021;12:14098-102. [PMID: 34760193 DOI: 10.1039/d1sc03526f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]